CAR T-cell Therapy

TC-510 for Mesothelioma

Phase 1 & 2
Research Sponsored by TCR2 Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upup to 2 years post-treatment
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

Eligible Conditions
  • Mesothelioma
  • Pancreatic Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Bile Duct Cancer
  • Pancreatic Adenocarcinoma
  • Ovarian Tumors
  • Non-Small Cell Lung Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1 - Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events.
Phase 2 - Disease Control Rate (DCR)
Phase 2 - Overall Response Rate (ORR)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lymphodepletion followed by TC-510Experimental Treatment3 Interventions
Lymphodepletion (fludarabine and cyclophosphamide) followed by TC-510 T cells
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 3

Find a site

Who is running the clinical trial?

TCR2 TherapeuticsLead Sponsor
2 Previous Clinical Trials
181 Total Patients Enrolled
1 Trials studying Mesothelioma
175 Patients Enrolled for Mesothelioma

Media Library

TC-510 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05451849 — Phase 1 & 2
Mesothelioma Research Study Groups: Lymphodepletion followed by TC-510
Mesothelioma Clinical Trial 2023: TC-510 Highlights & Side Effects. Trial Name: NCT05451849 — Phase 1 & 2
TC-510 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05451849 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are eligible to partake in the experiment?

"Affirmative. reveals that this experiment has been actively recruiting volunteers since June 21st 2022, with the most recent update occuring on September 21st 2022. The trial is looking for 115 subjects at 2 distinct medical facilities."

Answered by AI

Is the enrollment process for this trial currently open?

"This clinical trial is currently enrolling participants, as indicated on its page hosted by It was initially published on June 21st 2022 and has been amended most recently on September 21st 2022."

Answered by AI

Who else is applying?

What state do they live in?
How old are they?
18 - 65
What site did they apply to?
National Cancer Institute
What portion of applicants met pre-screening criteria?
Did not meet criteria
~80 spots leftby Jun 2025